A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization

Saeam Shin¹,², Juwon Kim³, Soo-Zin Kim-Wanner⁴, Halvard Bönig⁴,⁵,⁶, Sung Ran Cho⁷, Sinyoung Kim¹, Jong Rak Choi¹, Kyung-A Lee¹*

¹ Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, ² Department of Laboratory Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Korea, ³ Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, ⁴ German Red Cross Blood Service BaWüHe, Frankfurt, Germany, ⁵ Institute for Transfusion Medicine and Immune Hematology of the Johann-Wolfgang-Goethe Medical University, Frankfurt, Germany, ⁶ Department of Medicine/Hematology, University of Washington, Seattle, Washington, United States of America, ⁷ Department of Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea

* KAL1119@yuhs.ac

Abstract

Mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood is a complex mechanism that involves adhesive and chemotactic interactions of HSCs as well as their bone marrow microenvironment. In addition to a number of non-genetic factors, genetic susceptibilities also contribute to the mobilization outcome. Identification of genetic factors associated with HSC yield is important to better understand the mechanism behind HSC mobilization. In the present study, we enrolled 148 Korean participants (56 healthy donors and 92 patients) undergoing HSC mobilization for allogeneic or autologous HSC transplantation. Among a total of 53 polymorphisms in 33 candidate genes, one polymorphism (rs11264422) in relaxin/insulin-like family peptide receptor 4 (RXFP4) gene was significantly associated with a higher HSC yield after mobilization in Koreans. However, in a set of 101 Europeans, no association was found between circulating CD34+ cell counts and rs11264422 genotype. Therefore, we suggest that the ethnic differences in subjects’ genetic background may be related to HSC mobilization. In conclusion, the relaxin—relaxin receptor axis may play an important role in HSC mobilization. We believe that the results of the current study could provide new insights for therapies that use relaxin and HSC populations, as well as a better understanding of HSC regulation and mobilization at the molecular level.

Introduction

Hematopoietic stem cell (HSC) mobilization is a complex process that involves chemotactic factors, proteases, and adhesive molecules in bone marrow (BM) niches [1–3]. There is wide inter-individual variability in response to mobilization, and the outcome is hardly predictable...
despite several known demographic or clinical risk factors such as the following: age, sex, body mass index (BMI), ethnicity, diagnosis, and extent and duration of prior chemotherapy [4–8]. Inter-individual variation of HSC mobilization yield can be explained by a multifactorial model consisting of environmental and multiple genetic factors. Genetic contribution to mobilizing capacity is further supported by the fact that the second mobilization in the same donor typically yields similar results to those from the first mobilization [9,10].

Previous studies have reported genetic associations between single nucleotide polymorphisms (SNPs) and HSC mobilization yield [11–15]. Most of these SNPs are located in gene encoding molecules with known functional significance in the mobilization pathway, including C-X-C motif chemokine ligand 12 (CXCL12), vascular cell adhesion molecule 1 (VCAM1), CD44 (CD44), and colony stimulating factor 3 receptor (CSF3R) [11–15]. However, some of the results were not replicated in subsequent studies [11,16,17], and the responsible gene remains elusive.

Recent genome-wide association studies have shown that various hematologic traits of white blood cells (WBC), red blood cells, platelets, and CD34+ cells are highly heritable [18,19]. Previous studies have also indicated that each WBC subtype shares some associations which are probably attributable to shared process of differentiation and maintenance in BM and peripheral blood (PB) [18,20]. Therefore, we hypothesized that genetic factors associated with WBC count, neutrophil count, and circulating CD34+ cell count could also contribute to the regulation and migration of HSCs in BM niches and in PB.

The aim of this study was to identify genetic factors associated with HSC collection yield after mobilization in Korean population. We also attempted to determine whether our finding could be applied to other ethnic group of European ancestry.

**Methods**

**Participants**

A total of 148 Korean subjects, including 56 healthy donors for allogeneic HSC transplantation and 92 patients with hematologic disorders for autologous HSC transplantation, were prospectively recruited for this study. The European set was recruited to confirm the applicability of our findings, and consisted of 101 healthy donors of European ancestry from Germany. This study was approved by the institutional review board (IRB) of the Severance Hospital, Yonsei University College of Medicine (IRB No. 4-2013-0145). Written informed consent was obtained from all participants, in accordance with the Declaration of Helsinki.

**Mobilization and HSC collection**

For healthy donors, standard mobilization protocol was used with G-CSF (filgrastim 10 µg/kg daily), and collection was initiated on the fifth day after G-CSF initiation. Mobilization for patients undergoing autologous HSC transplantation was performed using G-CSF only or chemotherapy followed by G-CSF. Apheresis started when the PB leukocyte count reached 3.0 x 10^9/L after leukocyte nadir, in the case of combination with chemotherapy. Peak circulating CD34+ cell count (µL), collected just before apheresis, was assessed using a Stem-Kit (Beckman Coulter, Miami, FL, USA) for the Korean set and with a BD Stem Cell Enumeration kit (BD Biosciences, San Jose, CA, USA) for the European set. The CD34+ cell content in the first apheresis product was enumerated in 122 participants in the Korean set, and two additional outcomes were evaluated: total CD34+ cell count per donor body weight (/kg) obtained from the first apheresis; and CD34+ cell count (µL) from the first apheresis product.
Selection of target polymorphisms in candidate genes

To determine whether previously reported genetic associations with HSC yield might be applied to Koreans, we selected four common polymorphisms (rs1801157, rs1041163, rs13347, and rs3917924) in the following four genes: *CXCL12*, *VCAM1*, *CD44*, and *CSF3R* [11–17]. One polymorphism (rs2680880) in *CXCR4* was not included, as it was not found in East Asians (http://www.1000genomes.org/) [12]. To identify more candidate genes, we searched the literature for SNPs that are associated with WBC, neutrophil, or CD34+ cell counts [19–28] (Fig 1). Among the 64 additional SNPs, 15 with East Asian minor allele frequency of less than 0.05 were removed. Candidate genes were adopted from the literature or selected based on the functional relatedness to mobilization mechanism, such as cytokines, chemokines, proteases, and adhesion molecules (http://www.uniprot.org/) [2,3]. In total, 53 SNPs were selected for genotyping (Table 1).

SNP genotyping

Genomic DNA was extracted from PB leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Venlo, The Netherlands). The primer sequences for polymerase chain reaction (PCR) amplification and sequencing were designed using Primer3 software [29]. PCR was performed on 100 ng of genomic DNA, and sequencing was carried out using the BrightDye Terminator Cycle Sequencing Kit (Nimagen, Nijmegen, The Netherlands) on ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The results were compared with reference sequences using Sequencher 5.1 software (Gene Codes Corp., Ann Arbor, MI, USA). Quality of data was assessed using PHRED score for each base call [30]. The threshold for PHRED score was 20, based on the manufacturer’s instructions. In case of result with inadequate quality, sequencing was repeated and all genotype of tested locus were determined (no missing genotype data).

Statistical analysis

Following the Kolmogorov—Smirnov normality test, natural log transformation was applied on continuous outcome variables with skewed distribution for analysis. The association between continuous variables (age and BMI) and mobilization outcomes (CD34+ cell count in PB, total CD34+ cells/kg, and CD34+ cells in a product) were analyzed using Pearson correlation. The association between categorical variables (sex, diagnosis, BM involvement of disease, chemotherapy regimen history, mobilization protocol, and SNP genotype), and mobilization outcomes were analyzed using an independent two-sample t-test (for two categories) and analysis of variance (for three categories). Three subgroups were established for the genotype of each polymorphism: homozygous for the major allele, heterozygous and homozygous for the minor allele. We also tested three genetic models (dominant, recessive, and additive) using biallelic marker coding. SNPs with a raw \(P < 0.05\) in analysis with all three mobilization outcomes were included in multivariate linear regression analysis. Additional variables related to patient demographics or clinical history with \(P < 0.05\) shown in univariate analysis were included in multivariate analysis. Finally, the following variables were included in multivariate analysis according to each mobilization outcome: 1) CD34+ cell count in PB: sex, diagnosis, chemotherapy regimen history, and rs11264422 (*RXFP4*) genotype; 2) total CD34+ cells/kg: sex and *RXFP4* genotype; and 3) CD34+ cell count in a product: sex, BMI, diagnosis, and *RXFP4* genotype. False discovery rate (FDR) controlling procedure was used to adjust for multiple testing according to the genetic model [31]. \(P\) values < 0.05 were considered significant, and \(P\) values < 0.2 after FDR adjustment were considered to have a tendency [32]. Statistical analysis was performed using SPSS Statistics version 23.0.0 (IBM Corp., Armonk, NY, USA).
Fig 1. Flow diagram of target polymorphism selection. The diagram indicates inclusion and exclusion criteria for selection of target polymorphism.

https://doi.org/10.1371/journal.pone.0179986.g001
Table 1. List of 53 polymorphisms in 33 genes included in this study.

| rs ID          | Chromosome | Location (GRCh38. p2) | Candidate gene | Distance to gene | Protein function                              |
|---------------|------------|------------------------|----------------|------------------|-----------------------------------------------|
| rs11121242    | 1p36.23    | 8846242                | RERE           | 20 kb downstream  | Control of cell survival                      |
| rs6577536     | 1p36.23    | 8850051                | RERE           | 23 kb downstream  | Control of cell survival                      |
| rs11590606    | 1p36.23    | 8857610                | RERE           | 31 kb downstream  | Control of cell survival                      |
| rs10864368    | 1p36.23    | 8858254                | RERE           | 32 kb downstream  | Control of cell survival                      |
| rs3917924     | 1p34.3     | 36480052               | CSF3R          | Intron2           | Cell adhesion and chemotaxis                  |
| rs1041163     | 1p21.2     | 100718269              | VCAM1          | 1 kb upstream     | Cell adhesion and migration                    |
| rs6702883     | 1p21.1     | 104700458              | intergenic     |                  |                                               |
| rs4311917     | 1p13.3     | 107183121              | NTNG1          | Intron2           | Controlling axon growth                       |
| rs345275      | 1p13.3     | 107951181              | VAV3           | Intron1           | Regulation of cell adhesion                   |
| rs2365669     | 1p13.2     | 111820023              | KCND3          | Intron2           | Subunit of potassium channel                  |
| rs7523839     | 1p13.2     | 115630459              | VANGL1         | 11 kb upstream    | Multicellular organism development            |
| rs850610      | 1p13.1     | 116406090              | ATPIA1-AS1     | Exon 3            | Non-coding RNA                                |
| rs10923929    | 1p12       | 119963373              | NOTCH2         | Intron11          | Stem cell population maintenance              |
| rs11240089    | 1q21.1     | 14758715               | BCL2           | Intron1           | Cell migration                                |
| rs4657616     | 1q23.1     | 159001296              | ACKR1          | 202 kb upstream   | Chemokine receptor                            |
| rs2518564     | 1q23.1     | 159092646              | ACKR1          | 111 kb upstream   | Chemokine receptor                            |
| rs12075      | 1q23.1     | 159205564              | ACKR1          | Exon 2            | Chemokine receptor                            |
| rs12749069    | 1q23.1     | 154514584              | TDRD10         | Intron4           | Nucleotide binding                            |
| rs11264422    | 1q22       | 155938032              | RXFP4          | 3 kb upstream     | Relaxin-3 receptor                            |
| rs1962508     | 1q23.3     | 161975629              | DDR2           | 655 kb upstream   | Cell migration and remodeling of the extracellular matrix |
| rs2806424     | 1q23.3     | 162721669              | DDR2           | Intron4           | Cell migration and remodeling of the extracellular matrix |
| rs6426893     | 1q23.3     | 165058105              | intergenic     |                  |                                               |
| rs919679      | 1q24.1     | 166287925              | intergenic     |                  |                                               |
| rs6734238     | 2q13       | 113083453              | IL1F10         | 7 kb upstream     | Cytokine                                      |
| rs10932765    | 2q35       | 218234761              | ARPC2          | Intron5           | Cytoskeleton constituent                      |
| rs16850408    | 4q13.3     | 74067090               | CXCL2          | 29 kb upstream    | Chemokine                                     |
| rs546829      | 4q13.3     | 74090655               | CXCL2          | 6 kb upstream     | Chemokine                                     |
| rs9131        | 4q13.3     | 74097332               | CXCL2          | Exon 4            | Chemokine                                     |
| rs7667376     | 4q13.3     | 74102173               | CXCL2          | 2 kb downstream   | Chemokine                                     |
| rs1371799     | 4q13.3     | 74112120               | CXCL2          | 12 kb downstream  | Chemokine                                     |
| rs7686861     | 4q13.3     | 74132767               | CXCL2          | 33 kb downstream  | Chemokine                                     |
| rs2517524     | 6p21.33    | 31057936               | HCG22          | Intron3           | Non-coding RNA                                |
| rs2853946     | 6p21.33    | 31279426               | HLA-B          | 74 kb upstream    | Regulation of immune response                 |
| rs2844503     | 6p21.33    | 31474954               | HLA-B          | 117 kb downstream | Regulation of immune response                 |
| rs6936204     | 6p21.32    | 32249315               | intergenic     |                  |                                               |
| rs5020946     | 6p21.32    | 32482312               | BTNl2          | 73 kb downstream  | Regulation of T-cell proliferation            |
| rs4895441     | 6q23.3     | 135105435              | MYB            | 75 kb upstream    | Control of proliferation and differentiation of hematopoietic progenitor cells |
| rs12660713    | 6q23.3     | 135196858              | MYB            | Intron9           | Control of proliferation and differentiation of hematopoietic progenitor cells |
| rs976760      | 7p21.2     | 14234028               | DGKB           | Intron22          | Intracellular signal transduction             |

(Continued)
FDR adjusted \( P \) values were calculated using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA).

**Results**

**Patient characteristics**

Patient characteristics are summarized in Table 2. The group consisted of individuals who were diagnosed with acute leukemia (n = 8), non-Hodgkin lymphoma (n = 50), multiple myeloma (n = 33), and sarcoma (n = 1). On the first day of apheresis, the median circulating CD34+ count was 44 cells/\( \mu \)L in the Korean set and 93 cells/\( \mu \)L in the European set (healthy donors only for the latter).

**Relaxin/insulin-like family peptide receptor 4**

Of the 53 SNPs, only one polymorphism (rs11264422) made a significant difference in the three HSC mobilization outcomes of the Korean set (Table 3). The rs11264422 genotype, located 3 kb upstream of the relaxin/insulin-like family peptide receptor 4 (RXFP4) gene, was significantly associated with circulating CD34+ cells/\( \mu \)L (raw \( P = 0.03 \)), total CD34+ cells/kg (raw \( P = 0.008 \)), and product CD34+ cells/\( \mu \)L (raw \( P = 0.003 \)) (Fig 2). Three patients (two with lymphoma and one with multiple myeloma) who were homozygous for a minor allele (AA genotype) showed remarkably higher mobilization outcomes compared to both the 25 patients who were heterozygous (TA genotype) and the 120 who were homozygous (TT genotype) for the major allele. Moreover, the presence of A allele (TA+AA genotypes) showed significant association with higher CD34+ cells/\( \mu \)L in a product (raw \( P = 0.02 \)). Superior mobilizers (defined as >200 circulating CD34+ cells/\( \mu \)L) had the highest frequency (66.7%) of the AA genotype, followed by TA (12.0%) and TT (5.8%) genotypes (Fig 3). In contrast, poor mobilizers (defined as <20 circulating CD34+ cells/\( \mu \)L) had a higher frequency of the TT (25.0%) than TA (12.0%) genotype. However, for rs11264422 genotyping using the European set, the circulating CD34+ cell count did not differ between each genotype subgroup. SNP was at Hardy—Weinberg equilibrium in both Korean and European sets.
Univariate and multivariate analyses of host factors and mobilization outcomes

In univariate analysis, the circulating CD34+ cell count after mobilization was associated with sex, diagnosis, history of multiple chemotherapy regimens, and RXFP4 genotype in the Korean population (Table 4). In the European set, only a low BMI showed significant correlation with a low circulating CD34+ cell count \((P < 0.001)\). In the Korean set, the total CD34+ cell count/kg was associated with sex and RXFP4 genotype, while the CD34+ cell count in a product was associated with sex, BMI, diagnosis, and RXFP4 genotype.

Multivariate linear regression analysis revealed that female sex, diagnosis of acute leukemia, history of multiple chemotherapy regimens, and RXFP4 genotype (TT and TA) remained independently associated with lower circulating CD34+ cell count after mobilization in the Korean set (Table 5). Female sex and RXFP4 genotype (TT and TA) showed consistent significance when analyzed with other outcome variables, i.e., total CD34+ cell count/kg and CD34+ cell count in a product.

---

**Table 2. Characteristics of the participants in this study.**

| Characteristics                                      | n (%)/median (interquartile ranges) |
|------------------------------------------------------|-------------------------------------|
|                                                      | Korean set                          | European set                        |
| No.                                                  | 148                                 | 101                                 |
| Age (yr)                                             | 46 (32–56)                          | 32 (26–42)                          |
| Sex                                                  |                                     |                                     |
| Female                                               | 63 (42.6)                           | 26 (25.7)                           |
| Male                                                 | 85 (57.4)                           | 75 (74.3)                           |
| Body-mass index (kg/m²)                              | 24.4 (21.5–26.1)                    | 24.5 (22.4–28.0)                    |
| Diagnosis                                            |                                     |                                     |
| Healthy donor                                        | 56 (37.8)                           | 101 (100)                           |
| Acute leukemia                                       | 8 (5.4)                             | -                                   |
| Non-Hodgkin lymphoma                                 | 50 (33.8)                           | -                                   |
| Multiple myeloma                                     | 33 (22.3)                           | -                                   |
| Sarcoma                                              | 1 (0.7)                             | -                                   |
| BM involvement of disease                            |                                     |                                     |
| Present                                              | 51 (34.5)                           | -                                   |
| Absent                                               | 97 (65.5)                           | -                                   |
| Chemotherapy regimen history                         |                                     |                                     |
| Multiple regimens (three or more)                    | 9 (6.1)                             | -                                   |
| One or two regimens                                  | 139 (93.9)                          | -                                   |
| Mobilization                                         |                                     |                                     |
| Chemotherapy and G-CSF                               | 80 (54.1)                           | -                                   |
| G-CSF only                                           | 68 (45.9)                           | 101 (100)                           |
| CD34+ cell count (/μL) in PB                         | 44 (22–84)                          | 93 (67–116)                         |
| First apheresis product*                              |                                     |                                     |
| CD34+ cell count (/μL)                               | 1,418 (591–2,330)                   | -                                   |
| CD34+ cell count/kg donor \((×10⁶)\)                 | 3.54 (1.69–6.91)                    | -                                   |

PB, peripheral blood

*CD34+ cell count in an apheresis product was measured in 122 participants.

https://doi.org/10.1371/journal.pone.0179986.t002
In this study, we found that rs11264422 genotype, located in the promoter flanking region of RXFP4, has a significant effect on HSC mobilization. The RXFP4 gene encodes relaxin-3 receptor 2, which is a receptor for relaxin-3 and is expressed in various tissues including BM [33]. Relaxin-3 is a member of the insulin/relaxin superfamily of peptide hormones [34]. Segal et al. revealed that the relaxin hormone mobilizes BM-derived CD34+ endothelial progenitor cells into circulation, and their effect is mediated by the relaxin receptor [35]. The role of relaxin and its receptor-mediated pathway in HSC mobilization, as well as their association with the inter-individual variation of mobilization yield, can be hypothesized based on such observation.

### Table 3. Association of rs11264422 with mobilization outcomes

| Genotype | Korean set                      | European set                     |
|----------|---------------------------------|----------------------------------|
|          | CD34+ cells/μL in PB | CD34+ cells/kg (×10⁶) | CD34+ cells/kg in a product | CD34+ cells/μL in PB |
|          | n | Mean ± SD | Raw P | FDR P | n | Mean ± SD | Raw P | FDR P | n | Mean ± SD | Raw P | FDR P | n | Mean ± SD | Raw P | FDR P |
| TT       | 120 | 3.60 ± 1.28 | 0.03⁹** | 0.808⁹ | 98 | 1.11 ± 1.33 | 0.008⁹** | 0.424⁹ | 98 | 7.10 ± 1.39 | 0.003⁹** | 0.159⁹*** | 11 | 4.54 ± 0.31 | 0.5⁹ | |
| TA       | 25  | 3.85 ± 1.17 | 1.47 ± 1.25 | 21 | 21 | 7.58 ± 1.31 | 41 | 4.30 ± 0.68 | |
| AA       | 3   | 5.51 ± 0.51 | 3.44 ± 0.51 | 3 | 9.72 ± 0.45 | 49 | 4.41 ± 0.58 | |
| TT+TA    | 145 | 3.55 ± 1.41 | 0.01⁹** | 0.5⁹ | 119 | 1.20 ± 1.35 | 0.008⁹** | 0.4⁹ | 119 | 7.25 ± 1.42 | 0.003⁹** | 0.159⁹*** | 52 | 4.44 ± 0.54 | 0.3⁹ | |
| AA       | 3   | 5.51 ± 0.51 | 3.44 ± 0.51 | 3 | 9.72 ± 0.45 | 49 | 4.41 ± 0.58 | |
| TT       | 120 | 3.60 ± 1.28 | 1.47 ± 1.25 | 21 | 21 | 7.58 ± 1.31 | 41 | 4.30 ± 0.68 | |
| TA+AA    | 28  | 4.02 ± 1.23 | 1.71 ± 1.35 | 24 | 24 | 7.84 ± 1.43 | 90 | 4.36 ± 0.63 | |
| TT+AA    | 123 | 3.65 ± 1.33 | 1.23 ± 1.37 | 101 | 101 | 7.22 ± 1.44 | 60 | 4.41 ± 0.58 | 0.5⁹ | |
| TA       | 25  | 3.84 ± 1.17 | 1.47 ± 1.25 | 21 | 21 | 7.57 ± 1.31 | 41 | 4.35 ± 0.63 | |

PB, peripheral blood; SD, standard deviation; FDR, adjusted P value using false discovery rate controlling procedure

Natural log transformation was applied to mobilization outcomes due to skewed distribution.

Analysis of variance

Independent two-sample t-test

*P < 0.05

**P = 0.05

***P < 0.2 after FDR adjustment

Discussion

In this study, we found that rs11264422 genotype, located in the promoter flanking region of RXFP4, has a significant effect on HSC mobilization. The RXFP4 gene encodes relaxin-3 receptor 2, which is a receptor for relaxin-3 and is expressed in various tissues including BM [33]. Relaxin-3 is a member of the insulin/relaxin superfamily of peptide hormones [34]. Segal et al. revealed that the relaxin hormone mobilizes BM-derived CD34+ endothelial progenitor cells into circulation, and their effect is mediated by the relaxin receptor [35]. The role of relaxin and its receptor-mediated pathway in HSC mobilization, as well as their association with the inter-individual variation of mobilization yield, can be hypothesized based on such observation.

![Fig 2. Correlations between rs11264422 genotype and continuous outcomes](https://doi.org/10.1371/journal.pone.0179986.g002)
The FDR-adjusted $P$-values for rs11264422 were above the significance threshold ($P = 0.05$). However, we considered $P < 0.2$ after FDR adjustment as having a tendency for association. Given that the sample size was inadequate compared with the number of genes, we sought to find a possible exploratory factor. We determined three different mobilization outcomes and found consistent genes in all three. We then decided that the $P$-value of rs11264422 showed a meaningful trend, and wanted to suggest a further study. Therefore, we would like to conduct a confirmatory study using a larger number of patients.

The rs11264422 polymorphism has been associated with lower WBC counts in individuals of African, but not European, ancestry [28]. In our study, rs11264422 genotype was associated with HSC yield in Koreans but not in Europeans. Interestingly, the frequency of AA homozygote genotype is low in East Asians (1–4% in Japanese and Chinese) and Africans (0.2%), but distinctly higher in Europeans (43%). Moreover, in a previous randomized controlled trial in Japan, a higher baseline WBC count was associated with a lower incidence of poor mobilization [36]. Therefore, we infer that the mechanism involved in HSC mobilization differs by ethnic groups, and rs11264422 genotype is associated with the HSC mobilization yield as well as the baseline WBC count in certain populations. Moreover, associations between the four polymorphisms in CXCL12, VCAM1, CD44, and CSF3R and mobilization outcome were not replicated in our study. Previous studies have already noted discrepancies in genetic associations, which were likely attributed to differences in ethnicity, diagnosis, number of study participants, and definition of outcome [13–17]. In particular, most of the previous studies had
targeted those of European ancestry, whereas our study is the first to target the East Asian population. Therefore, our results suggest that there are significant differences in molecular mechanisms underlying HSC mobilization between different ethnic groups. Our preliminary data warrant further validation with larger cohorts of various population subgroups.

The therapeutic effect of circulating CD34+ cells has been demonstrated in hematologic disorders and cardiovascular diseases [37,38]. In this context, the promotion of vasculogenesis is thought to be a mechanism for efficacy of CD34+ progenitor cells [19]. Notably, serelaxin, which is a recombinant human relaxin-2, has demonstrated significant treatment effects on acute heart failure in a recent clinical trial [39]. The potential mechanisms behind beneficial effects of serelaxin in acute heart failure include vasodilation, tissue healing from stimulation of angiogenesis and stem cell survival, and remodeling of the extracellular matrix [40]. Furthermore, a recent experimental study demonstrated that relaxin improves wound healing in

### Table 4. Factors associated with mobilization outcomes in the univariate analysisa.

| Variables                      | Korean set | European set |
|--------------------------------|------------|--------------|
|                                | CD34+ cells/μL in PB | CD34+ cells/kg (×10^6) | CD34+ cells/μL in a product | CD34+ cells/μL in PB |
|                                | r, mean ± SD | P value | r, mean ± SD | P value | r, mean ± SD | P value | r, mean ± SD | P value |
| Age (yr)                       | -0.064      | 0.4^c      | -0.014       | 0.9^c    | 0.096       | 0.3^c    | 0.007       | 0.9^c    |
| Sex                            | 0.001^c    | 0.002^c    | <0.001^c    | 0.06^c  |
| Male                           | 3.99 ± 1.20 | 1.87 ± 1.01 | 7.70 ± 1.42 | 4.47 ± 0.51 |
| Female                         | 3.34 ± 1.19 | 1.34 ± 0.77 | 6.65 ± 1.19 | 4.15 ± 0.78 |
| Body-mass index (kg/m^2)       | 0.155      | 0.06^b      | 0.112       | 0.2^b    | 0.204       | 0.02^b    | 0.343       | <0.001^b  |
| Diagnosis                      | <0.001^b   | 0.08^d      | 0.01^d      | -       |
| Healthy donor                  | 3.88 ± 0.57 | 1.74 ± 0.39 | 6.81 ± 0.58 |
| Acute leukemia                 | 2.07 ± 1.04 | 0.81 ± 0.55 | 6.16 ± 1.27 |
| Non-Hodgkin lymphoma/sarcoma   | 3.73 ± 1.68 | 1.69 ± 1.22 | 7.61 ± 1.05 |
| Multiple myeloma               | 3.87 ± 0.96 | 1.67 ± 0.95 | 7.61 ± 1.05 |
| BM involvement of disease      | 0.2^c      | 0.4^c      | 0.4^c      | -       |
| Absent                         | 3.80 ± 1.17 | 1.69 ± 0.94 | 7.16 ± 1.43 |
| Present                        | 3.55 ± 1.35 | 1.56 ± 0.96 | 7.37 ± 1.40 |
| Chemotherapy regimen history   | 0.04^c**   | 0.09^c    | 0.3^c      | -       |
| One or two regimens            | 3.77 ± 1.22 | 1.68 ± 0.95 | 7.29 ± 1.41 |
| Multiple regimens (three or more) | 2.89 ± 1.27 | 1.14 ± 0.85 | 6.72 ± 1.52 |
| Mobilization                   | 0.8^c      | 0.9^c      | 0.7^c      | -       |
| G-CSF only                     | 3.69 ± 1.28 | 1.64 ± 0.97 | 7.30 ± 1.45 |
| Chemotherapy and G-CSF         | 3.74 ± 1.20 | 1.64 ± 0.93 | 7.19 ± 1.40 |
| RXFP4 genotype                 | 0.03^d*    | 0.008^d*  | 0.003^d*  | 0.5^d   |
| TT                             | 3.60 ± 1.28 | 1.11 ± 1.33 | 7.10 ± 1.39 | 4.54 ± 0.31 |
| TA                             | 3.85 ± 1.17 | 1.47 ± 1.25 | 7.58 ± 1.31 | 4.30 ± 0.68 |
| AA                             | 5.51 ± 0.51 | 3.44 ± 0.51 | 9.72 ± 0.45 | 4.41 ± 0.58 |

*aNatural log transformation was applied to mobilization outcomes due to skewed distribution. Data were represented as correlation coefficient (r) or mean ± standard deviation.

*bPearson correlation test

*cIndependent two-sample t-test

*dAnalysis of variance

*e50 patients with non-Hodgkin lymphoma and one with sarcoma were included.

*P < 0.05

https://doi.org/10.1371/journal.pone.0179986.t004
In that study, the wound-healing effect of relaxin was disturbed by antibodies against vascular endothelial growth factor, CXCR4, and CXCR12 [41]. Our data support previous assumptions about the effects of relaxin on vasculogenic capacity and stem cell/progenitor cell regulation, and suggest a broader applicability of relaxin to other vascular disorders such as diabetes mellitus. In addition, our data also suggest that relaxin is a novel agent for the management of poor mobilizers. Among host risk factors, female sex, history of multiple chemotherapy regimens, and diagnosis of acute leukemia remained independently associated with low circulating CD34+ cell counts in Koreans. Male sex [4,42], prior treatment history [1], and diagnosis of acute leukemia [43] have all been known to be independent risk factors for poor mobilization. The mechanism behind association of sex and better mobilization potential can be explained by the stem cell regulation effect of sex steroids [44]. The contribution of an underlying hematologic disease on HSC mobilization can be explained by disease-related reduction of HSC reservoir, or chemotherapy-induced toxic effects on BM [43]. In the European set, only BMI correlated with circulating CD34+ cell counts. The mechanism behind association between higher BMI and better mobilization potential has been attributed to the effect of adipose tissue-containing HSCs, or a simple dose effect of G-CSF [8].

To the best of our knowledge, this is the first study to indicate an association between relaxin receptor polymorphism and HSC yield after mobilization. A potential limitation of our study is that the discovered locus is located in the regulatory region of RXFP4, and not in the protein-coding region. Further investigation regarding the functional effect of relaxin-3, as well as its receptor axis on the mobilization process, are required.

In conclusion, we found a novel association between relaxin receptor polymorphism and HSC yield after mobilization in ethnic Koreans. Our findings suggest an important functional role of relaxin axis during response of BM HSCs to the mobilizing agent. Results of our study...

| Variables | CD34+ cells/μL in PB | CD34+ cells/kg (×10^6;) | CD34+ cells/μL in a product |
|-----------|------------------|---------------------|-------------------------|
|           | β (95% CI)       | P value             | β (95% CI)               | P value               | β (95% CI) | P value               |
| Sex       |                  |                     |                         |                       |           |                       |
| Male      | Reference        |                     | Reference               |                       |           |                       |
| Female    | -0.660 (-1.028, -0.292) | 0.001*             | -0.630 (-1.018, -0.242) | 0.002*               | -0.590 (-0.987, -0.193) | 0.004*               |
| Body-mass index (kg/m^2) | 0.025 (-0.301, 0.081) | 0.4 |  |  |  |  |
| Diagnosis |                  |                     |                         |                       |           |                       |
| Healthy donor | Reference    |                     | Reference               |                       |           |                       |
| Acute leukemia | -1.722 (-2.545, -0.898) | <0.001*            | -1.737 (-2.574, -0.901) | <0.001*               |
| Non-Hodgkin lymphoma/sarcoma* | -0.259 (-0.701, 0.183) | 0.2              | -0.368 (-0.803, 0.068) | 0.09            |
| Multiple myeloma | -0.057 (-0.551, 0.437) | 0.8          | -0.150 (-0.653, 0.353) | 0.6               |
| Chemotherapy regimen history |                  |                     |                         |                       |           |                       |
| Multiple regimens (three or more) | Reference  |                     | Reference               |                       |           |                       |
| One or two regimens | 0.877 (0.100, 1.654) | 0.03*          |  |  |  |  |
| RXFP4 genotype |                  |                     |                         |                       |           |                       |
| TT        |                  |                     |                         |                       |           |                       |
| TA        | 0.091 (-0.405, 0.588) | 0.7              | 0.166 (-0.347, 0.678) | 0.5               | 0.122 (-0.382, 0.626) | 0.6               |
| AA        | 1.735 (0.446, 3.024) | 0.009*           | 1.809 (0.452, 3.166) | 0.009*              | 1.830 (0.526, 3.135) | 0.006*              |
| a50 patients with non-Hodgkin lymphoma and one with sarcoma were included.  
* P < 0.05
give valuable insight to a potential therapeutic target—the relaxin—relaxin receptor axis—for the management of poor mobilizers, and for the treatment of various vascular diseases.

**Supporting information**

S1 File. Table A. Association of 53 polymorphisms with mobilization outcomes. (XLSX)

**Author Contributions**

**Conceptualization:** Saeam Shin, Kyung-A Lee.

**Data curation:** Saeam Shin, Soo-Zin Kim-Wanner.

**Formal analysis:** Saeam Shin.

**Funding acquisition:** Kyung-A Lee.

**Investigation:** Saeam Shin, Juwon Kim, Soo-Zin Kim-Wanner, Halvard Bönig, Sung Ran Cho.

**Methodology:** Saeam Shin, Kyung-A Lee.

**Project administration:** Kyung-A Lee.

**Resources:** Juwon Kim, Soo-Zin Kim-Wanner, Halvard Bönig, Sung Ran Cho, Jong Rak Choi.

**Supervision:** Kyung-A Lee.

**Writing – original draft:** Saeam Shin.

**Writing – review & editing:** Juwon Kim, Halvard Bönig, Sung Ran Cho, Sinyoung Kim, Kyung-A Lee.

**References**

1. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011; 118: 4530–4540. https://doi.org/10.1182/blood-2011-06-318220 PMID: 21832280

2. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood. 2004; 103: 1580–1585. https://doi.org/10.1182/blood-2003-05-1595 PMID: 14604975

3. Wilson A, Trump A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006; 6: 93–106. https://doi.org/10.1038/nri1779 PMID: 16491134

4. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008; 112: 2092–2100. https://doi.org/10.1182/blood-2008-03-143677 PMID: 18523146

5. Armean RM, Alshemmarie SH, Alqallaf D. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma. 2008; 8: 106–110. https://doi.org/10.3816/CLM.2008.n.012 PMID: 18501104

6. Cottler-Fox M, Lapidot T. Mobilizing the older patient with myeloma. Blood Rev. 2006; 20: 43–50. https://doi.org/10.1016/j.bire.2005.06.001 PMID: 16125290

7. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006; 37: 719–724. https://doi.org/10.1038/sj.bmt.1705298 PMID: 16518434

8. Teipel R, Schetelig J, Kramer M, Schmidt H, Schmidt AH, Thiede C, et al. Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. Transfusion. 2015; 55: 2855–2863. https://doi.org/10.1111/trf.13239 PMID: 26183707

9. De la Rubia J, Arbóna C, Del Canizo C, Arrieta R, De Arriba F, Pascual MJ, et al. Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+)
13. Ben Nasr M, Reguaya Z, Berraies L, Maamar M, Ladeb S, Ben Othmen T, et al. Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in a Tunisian population. Transplant Proc. 2011; 43: 635–638. https://doi.org/10.1016/j.transproceed.2011.01.016 PMID: 21440782

14. Benboubker L, Watier H, Carion A, Georget MT, Desbois I, Colombat P, et al. Association between the SDF1-3'A allele and high levels of CD34+ progenitor cells mobilized into peripheral blood in humans. British journal of haematology. 2001; 113: 247–250. PMID: 11329308

15. Bogunia-Kubik K, Gieryng A, Dlubek D, Lange A. The CXCL12-3'A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantation. Bone Marrow Transplant. 2009; 44: 273–278. https://doi.org/10.1038/bmt.2009.30 PMID: 19252530

16. Lenk J, Bornhauser M, Kramer M, Hölig K, Poppe-Thiède K, Schmidt H, et al. Sex and Body Mass Index but not CXCL12 B01 G/A Polymorphism Determine the Efficacy of Hematopoietic Cell Mobilization: A Study in Healthy Volunteer Donors. Biology of Blood and Marrow Transplantation. 2013; 19: 1517–1521. https://doi.org/10.1016/j.bbmt.2013.07.018 PMID: 23891749

17. Schulz M, Karpova D, Spohn G, Damert A, Seifried E, Binder V, et al. Variant rs1801157 in the 3'UTR of PSMD3–CSF3 and PLCB4 are associated with neutrophil count. Hum Mol Genet. 2010; 19: 2079–2085. https://doi.org/10.1038/hmg/ddq080 PMID: 20172861

18. Okada Y, Kamatani Y, Takahashi A, Ohmiya H, Kumasaka N, et al. Identification of nine novel loci associated with white blood cell subtypes in a Japanese population. PLoS Genet. 2011; 7: e1002067. https://doi.org/10.1371/journal.pgen.1002067 PMID: 21738478

19. Okada Y, Hirota T, Kamatani Y, Takahashi A, Ohmiya H, Kumasaka N, et al. Identification of nine novel loci associated with white blood cell subtypes in a Japanese population. PLoS Genet. 2011; 7: e1002067. https://doi.org/10.1371/journal.pgen.1002067 PMID: 21738478

20. Abecasis GR, Reiner AP, Lettge G, Nalls MA, Ganesh SK, Mathias R, et al. Genome-Wide Association Study of White Blood Cell Count in 16,388 African Americans: the Continental Origins and Genetic Epidemiology Network (COGENT). PLoS Genetics. 2011; 7: e1002108. https://doi.org/10.1371/journal. pgen.1002108 PMID: 21738479

21. Reich D, Nalls MA, Kao WL, Akyelbekova EL, Tandon A, Patterson N, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genetics. 2009; 5: e1000360. https://doi.org/10.1371/journal.pgen.1000360 PMID: 19180233

22. Soranzo N, Spector TD, Mangino M, Kühnel B, Rendon A, Teumer A, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009; 41: 1182–1190. https://doi.org/10.1038/ng.467 PMID: 19820697

23. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010; 42: 210–215. https://doi.org/10.1038/ng.531 PMID: 20139978

24. Okada Y, Kamatani Y, Takahashi A, Matsuda K, Hosono N, Ohmiya H, et al. Common variations in PSMD3–CSF3 and PLCB4 are associated with neutrophil count. Hum Mol Genet. 2010; 19: 2079–2085. https://doi.org/10.1038/hmg/ddq080 PMID: 20172861

25. Nalls MA, Couper DJ, Tanaka T, van Rooij FJ, Chen MH, Smith AV, et al. Multiple loci are associated with white blood cell phenotypes. PLoS Genet. 2011; 7: e1002113. https://doi.org/10.1371/journal. pgen.1002113 PMID: 21738480
27. Kong M, Lee C. Genetic associations with C-reactive protein level and white blood cell count in the KARE study. Int J Immunogenet. 2013; 40: 120–125. https://doi.org/10.1111/j.1744-313X.2012.01141.x PMID: 22788528

28. Nalls MA, Wilson JG, Patterson NJ, Tandon A, Zmuda JM, Huntsman S, et al. Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet. 2008; 82: 81–87. https://doi.org/10.1016/j.ajhg.2007.09.003 PMID: 18179887

29. Unteragger A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3—new capabilities and interfaces. Nucleic Acids Res. 2012; 40: e115. https://doi.org/10.1093/nar/gks596 PMID: 22730293

30. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 1998; 8: 186–194. PMID: 9521922

31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the royal statistical society. Series B (Methodological). 1995; 289–300.

32. Lentner C, Diem K, Seldrup J. Geigy scientific tables. Volume 2: introduction to statistics, statistical tables, mathematical formulae. Basle: Ciba-Geigy; 1982.

33. Boels K, Schaller HC. Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor. Br J Pharmacol. 2003; 140: 932–938. https://doi.org/10.1038/sj.bjp.0705521 PMID: 14530218

34. Rosengren KJ, Lin F, Bathgate RA, Tregar G W, Daly NL, Wade JD, et al. Solution structure and novel insights into the determinants of the receptor specificity of human relaxin-3. J Biol Chem. 2006; 281: 5845–5851. https://doi.org/10.1074/jbc.M51210200 PMID: 16365033

35. Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J, et al. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood. 2012; 119: 629–636. https://doi.org/10.1182/blood-2011-04-346007 PMID: 22028476

36. Komeno Y, Kanda Y, Hamaki T, Mitani K, Iijima K, Ueyama J, et al. A randomized controlled trial to compare once- versus twice-daily filgrastim for mobilization of peripheral blood stem cells from healthy donors. Biol Blood Marrow Transplant. 2006; 12: 408–413. https://doi.org/10.1016/j.bbmt.2005.11.007 PMID: 16545724

37. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011; 109: 428–436. https://doi.org/10.1161/CIRCRESAHA.111.245993 PMID: 21737787

38. Gupta R, Losordo DW. Cell therapy for critical limb ischemia: moving forward one step at a time. Circ Cardiovasc Interv. 2011; 4: 2–5. https://doi.org/10.1161/CIRCINTERVENTIONS.110.960716 PMID: 23141816

39. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381: 29–39. https://doi.org/10.1016/S0140-6736(12)61855-8 PMID: 23141816

40. Tietjens J, Teerlink JR. Serelaxin and acute heart failure. Heart. 2016; 102: 95–99. https://doi.org/10.1136/heartjnl-2014-306786 PMID: 26603680

41. Bitto A, Irreia N, Minutoli L, Carlo M, Lo Cacio P, Caccia P, et al. Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice. Clin Sci (Lond). 2013; 125: 575–585.

42. Wang TF, Wen SH, Chen RL, Lu CJ, Zheng YJ, Yang SH, et al. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant. 2008; 14: 1305–1311. https://doi.org/10.1016/j.bbmt.2008.09.002 PMID: 18940686

43. Koenigsmann M, Jentsch-Ulrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion. 2004; 44: 777–784. https://doi.org/10.1111/j.1537-2995.2004.00321.x PMID: 15104662

44. Wang X, Mamillapalli R, Mutlu L, Du H, Taylor HS. Chemoattraction of bone marrow-derived stem cells towards human endometrial stromal cells is mediated by estradiol regulated CXCL12 and CXCR4 expression. Stem cell research. 2015; 15: 14–22. https://doi.org/10.1016/j.scr.2015.04.004 PMID: 25957946